Finanzen von Rockwell Medical Inc (RMTI)RMTIRockwell Medical Inc

Rockwell Medical Inc (RMTI) generates its revenue primarily from Concentrate Products, which accounts for 100.0% of total sales, equivalent to $17.78M. Understanding this concentration is critical for investors evaluating how RMTI navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Rockwell Medical Inc maintains a gross margin of 18.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.97%, while the net margin is -6.59%. These profitability ratios, combined with a Return on Equity (ROE) of -16.00%, provide a clear picture of how effectively RMTI converts its operational activities into shareholder value.

In the context of the broader market, RMTI competes directly with industry leaders such as ARAY and XTLB. With a market capitalization of $32.93M, it holds a leading position in the sector. When comparing efficiency, RMTI's gross margin of 18.24% stands against ARAY's 34.76% and XTLB's N/A. Such benchmarking helps identify whether Rockwell Medical Inc is trading at a premium or discount relative to its financial performance.

Rockwell Medical has shown fluctuating revenue, with total revenue for Q2 2026 at $17.78 million, but has faced net losses in recent quarters, including a net loss of $1.32 million in Q2 2026. Gross margin has varied, with a recent gross margin of 18.24%.